• 1
    Allard P, Bernard P, Fradet Y, Tetu B. The early clinical course of primary Ta and t1 bladder cancer: a proposed prognostic index. Br. J. Urol. 1998; 81: 6928.
  • 2
    Kurth KH, Denis L, Bouffioux C et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur. J. Cancer 1995; 31A: 18406.
  • 3
    Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J. Urol. 2000; 163: 738.
  • 4
    Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 2006; 49: 4665.
  • 5
    Akagashi K, Tanda H, Kato S et al. Recurrence pattern for superficial bladder cancer. Int. J. Urol. 2006; 13: 68691.
  • 6
    Nomi M, Gohji K, Okamoto M, Takenaka A, Ono Y, Fujii A. Results of transurethral resection plus adjuvant intravesical chemotherapy for superficial bladder cancer. Int. J. Urol. 1998; 5: 5349.
  • 7
    Sakai I, Miyake H, Harada K, Hara I, Inoue TA, Fujisawa M. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ. Int. J. Urol. 2006; 13: 138992.
  • 8
    Takashi M, Wakai K, Hattori T et al. Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guerin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ. Int. Urol. Nephrol. 2002; 33: 417.
  • 9
    Japanese Urological Association, The Japanese Society of Pathology. General Rule for Clinical and Pathological Studies on Bladder Cancer, 2nd edn. Kanehara & Co. Ltd, Tokyo, 1993.
  • 10
    Japanese Urological Association, The Japanese Society of Pathology. General Rule for Clinical and Pathological Studies on Bladder Cancer, 3rd edn. Kanehara & Co. Ltd, Tokyo, 2001.
  • 11
    Hara I, Miyake H, Takechi Y et al. Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder. Int. J. Urol. 2003; 10: 1924.
  • 12
    Lamm DL, van der Meijden AP, Akaza H et al. Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? Int. J. Urol. 1995; 2: 2335.
  • 13
    Lee C, Park MS. Prophylactic treatment of superficial bladder tumor. Int. J. Urol. 1998; 5: 51120.
  • 14
    Hall MC, Chang SS, Dalbagni G et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J. Urol. 2007; 178: 231430.
  • 15
    Oosterlinck W, Lobel B, Jakse G, Malmstrom PU, Stockle M, Sternberg C. Guidelines on bladder cancer. Eur. Urol. 2002; 41: 10512.
  • 16
    Au JL, Badalament RA, Wientjes MG et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J. Natl. Cancer Inst. 2001; 93: 597604.
  • 17
    Huncharek M, Geschwind JF, Witherspoon B, McGarry R, Adcock D. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J. Clin. Epidemiol. 2000; 53: 67680.
  • 18
    Frydenberg M, Millar JL, Toner G et al. Management of superficial bladder cancer in Victoria: 1990 and 1995. ANZ J. Surg. 2005; 75: 2704.
  • 19
    Gardmark T, Bladstrom A, Hellsten S, Malmstrom PU, Members of the Swedish National Bladder Cancer Registry. Analysis of clinical characteristics, management and survival of patients with Ta T1 bladder tumours in Sweden between 1997 and 2001. Scand. J. Urol. Nephrol. 2006; 40: 27682.
  • 20
    Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int. J. Urol. 2005; 12: 4661.
  • 21
    Okuyama A, Kohri K, Akaza H et al. The report of clinical statistical studies on registered bladder cancer patients in Japan 1999–2001. Nippon Hinyoukika Gakkai Zasshi 2006; 97: NP231. (In Japanese.)
  • 22
    Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J. Urol. 1997; 158: 627.
  • 23
    Holmang S, Hedelin H, Anderstrom C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J. Urol. 1995; 153: 18236.